scholarly journals TNF inhibitors for the prevention of Alzheimer’s disease: Preliminary findings from the rheumatoid arthritis medication and memory study (RESIST)

2021 ◽  
Vol 17 (S9) ◽  
Author(s):  
Bethany McDowell ◽  
Clive Holmes ◽  
Christopher J Edwards ◽  
Christopher Cardwell ◽  
Michelle McHenry ◽  
...  
CNS Drugs ◽  
2016 ◽  
Vol 30 (11) ◽  
pp. 1111-1120 ◽  
Author(s):  
Richard C. Chou ◽  
Michael Kane ◽  
Sanjay Ghimire ◽  
Shiva Gautam ◽  
Jiang Gui

1999 ◽  
Vol 10 (2) ◽  
pp. 97-100
Author(s):  
F Nourhashémi ◽  
S Andrieu ◽  
M.L Soléra ◽  
Y Rolland ◽  
P.J Ousset ◽  
...  

2011 ◽  
Vol 6 (1) ◽  
pp. 33 ◽  
Author(s):  
Christopher R Simmons ◽  
Fanggeng Zou ◽  
Steven G Younkin ◽  
Steven Estus

The Lancet ◽  
1991 ◽  
Vol 337 (8754) ◽  
pp. 1426 ◽  
Author(s):  
C.Mary Beard ◽  
Emre Kokman ◽  
LeonardT. Kurland

2019 ◽  
Author(s):  
Shea J Andrews ◽  
Alison Goate

AbstractINTRODUCTIONEpidemiological research has suggested that inhibition of tumor necrosis factor (TNF)-α in patients with rheumatoid arthritis (RA) reduces the overall risk of Alzheimer’s disease (AD). TNF-α antagonists have been suggested as a potential treatment for AD.METHODSWe used a two-sample Mendelian randomization design to examine the causal relationship between blood TNF expression, serum TNF-α levels, and RA on AD risk.RESULTSOur results do not support a causal relationship between TNF expression, serum TNF-α levels or RA on AD risk.DISCUSSIONThese results suggest that TNF-α antagonists are unlikely to reduce the risk of AD.


Sign in / Sign up

Export Citation Format

Share Document